Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Anticholesteremic Agents"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-25 z 6500
Tytuł:
LDL cholesterol target attainment in cardiovascular high- and very-high-risk patients with statin intolerance: a simulation study.
Autorzy:
Katzmann JL; Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany. .
Stürzebecher PE; Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany.
Kruppert S; IQVIA Germany, Frankfurt am Main, Germany.
Laufs U; Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Jan 04; Vol. 14 (1), pp. 474. Date of Electronic Publication: 2024 Jan 04.
Typ publikacji:
Journal Article
MeSH Terms:
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/adverse effects
Anticholesteremic Agents*
Humans ; Cholesterol, LDL ; Drug Therapy, Combination ; Ezetimibe/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus.
Autorzy:
Han JH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Joung KH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.; Division of Endocrinology and Metabolism, Department of International Medicine, Chungnam National University Sejong Hospital, Sejong, Korea.
Lee JC; Division of Endocrinology and Metabolism, Department of Internal Medicine, Eulji University School of Medicine, Daejeon, Korea.
Kim OS; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Choung S; Department of Medical Science, Chungnam National University College of Medicine, Daejeon, Korea.
Kim JM; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.; Division of Endocrinology and Metabolism, Department of International Medicine, Chungnam National University Sejong Hospital, Sejong, Korea.
Kang YE; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Yi HS; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.; Laboratory of Endocrinology and Immune System, Chungnam National University College of Medicine, Daejeon, Korea.
Lee JH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Ku BJ; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Kim HJ; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Pokaż więcej
Źródło:
Diabetes & metabolism journal [Diabetes Metab J] 2024 Jan; Vol. 48 (1), pp. 112-121. Date of Electronic Publication: 2024 Jan 03.
Typ publikacji:
Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms:
Anticholesteremic Agents*/therapeutic use
Diabetes Mellitus, Type 2*/drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Insulin Resistance*
Humans ; Cholesterol, LDL ; Drug Therapy, Combination ; Ezetimibe/therapeutic use ; Rosuvastatin Calcium/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Comparison of the efficacy and safety of Shanhuang Jiangzhi tablets and atorvastatin in the treatment of patients with hyperlipidaemia.
Autorzy:
Sun G; Suzhou Medical College of Soochow University, Soochow University, Suzhou, 215000, China.; Department of Cardiology, Hulunbuir Zhong Meng Hospital, No. 58 West Street, Hailar District, Hulunbuir, 021000, China.; Department of Cardiology, Shouguang Hospital of T.C.M, Weifang, 262700, China.
Liang X; Suzhou Medical College of Soochow University, Soochow University, Suzhou, 215000, China. .; Department of Cardiology, Hulunbuir Zhong Meng Hospital, No. 58 West Street, Hailar District, Hulunbuir, 021000, China. .
Pokaż więcej
Źródło:
Journal of health, population, and nutrition [J Health Popul Nutr] 2023 Dec 14; Vol. 42 (1), pp. 143. Date of Electronic Publication: 2023 Dec 14.
Typ publikacji:
Journal Article
MeSH Terms:
Hyperlipidemias*/drug therapy
Hyperlipidemias*/chemically induced
Anticholesteremic Agents*/adverse effects
Heptanoic Acids*/adverse effects
Humans ; Atorvastatin/adverse effects ; Cholesterol, LDL/therapeutic use ; Retrospective Studies ; Pyrroles/adverse effects ; Lipids/therapeutic use ; Triglycerides ; Cholesterol, HDL/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
Autorzy:
Imran TF; Providence VA Medical Center, Providence, Rhode Island, United States of America.; Lifespan Cardiovascular Institute, Rhode Island and Miriam Hospitals, Providence, Rhode Island, United States of America.; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Khan AA; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Has P; Lifespan Cardiovascular Institute, Rhode Island and Miriam Hospitals, Providence, Rhode Island, United States of America.; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Jacobson A; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Bogin S; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Khalid M; Lifespan Cardiovascular Institute, Rhode Island and Miriam Hospitals, Providence, Rhode Island, United States of America.
Khan A; Northwestern University, Evanston, Illinois, United States of America.
Kim S; Weil Cornell College of Medicine, New York, New York, United States of America.
Erqou S; Providence VA Medical Center, Providence, Rhode Island, United States of America.; Lifespan Cardiovascular Institute, Rhode Island and Miriam Hospitals, Providence, Rhode Island, United States of America.; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Choudhary G; Providence VA Medical Center, Providence, Rhode Island, United States of America.; Lifespan Cardiovascular Institute, Rhode Island and Miriam Hospitals, Providence, Rhode Island, United States of America.; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Aspry K; Lifespan Cardiovascular Institute, Rhode Island and Miriam Hospitals, Providence, Rhode Island, United States of America.; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Wu WC; Providence VA Medical Center, Providence, Rhode Island, United States of America.; Lifespan Cardiovascular Institute, Rhode Island and Miriam Hospitals, Providence, Rhode Island, United States of America.; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Dec 06; Vol. 18 (12), pp. e0295359. Date of Electronic Publication: 2023 Dec 06 (Print Publication: 2023).
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Myocardial Infarction*/drug therapy
Atherosclerosis*/drug therapy
Anticholesteremic Agents*/therapeutic use
Cardiovascular Diseases*/drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Humans ; PCSK9 Inhibitors ; Cholesterol, LDL ; Proprotein Convertase 9/genetics ; Heart Disease Risk Factors ; RNA, Small Interfering/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of moderate-intensity statin with ezetimibe combination vs. high-intensity statin therapy according to sex in patients with atherosclerosis.
Autorzy:
Kim BG; Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea.
Lee SJ; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea.
Lee YJ; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea.
You SC; Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea.
Hong SJ; Korea University College of Medicine, Seoul, Korea.
Yun KH; Wonkwang University Hospital, Iksan, Korea.
Hong BK; Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Heo JH; Kosin University College of Medicine, Busan, Korea.
Rha SW; Korea University Guro Hospital, Seoul, Korea.
Hong SJ; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea.
Ahn CM; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea.
Kim BK; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea.
Ko YG; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea.
Choi D; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea.
Hong MK; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea.
Jang Y; CHA Bundang Medical Center, CHA University College of Medicine, Seongnam, Korea.
Cho YH; Division of Cardiology, Myongji Hospital, Hwasu-ro 14-55, Deogyang-gu, Goyang, 10475, Gyeonggi-do, Korea. .
Kim JS; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Nov 17; Vol. 13 (1), pp. 20157. Date of Electronic Publication: 2023 Nov 17.
Typ publikacji:
Journal Article
MeSH Terms:
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Anticholesteremic Agents*
Atherosclerosis*/drug therapy
Atherosclerosis*/chemically induced
Humans ; Female ; Male ; Ezetimibe/therapeutic use ; Rosuvastatin Calcium ; Cholesterol, LDL ; Drug Therapy, Combination ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study.
Autorzy:
Moon JS; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Park IR; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Kim SS; Department of Internal Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
Kim HS; Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
Kim NH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul.
Kim SG; Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul.
Ko SH; Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
Lee JH; Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.
Lee I; Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.
Lee BK; Clinical Operation Team, Yuhan Corporation, Seoul, Korea.
Won KC; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Pokaż więcej
Źródło:
Diabetes & metabolism journal [Diabetes Metab J] 2023 Nov; Vol. 47 (6), pp. 818-825. Date of Electronic Publication: 2023 Nov 24.
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase IV; Journal Article
MeSH Terms:
Anticholesteremic Agents*/adverse effects
Hypercholesterolemia*
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Cardiovascular Diseases*/epidemiology
Cardiovascular Diseases*/etiology
Cardiovascular Diseases*/prevention & control
Atherosclerosis*/drug therapy
Atherosclerosis*/epidemiology
Humans ; Rosuvastatin Calcium/adverse effects ; Ezetimibe/adverse effects ; Cholesterol, LDL ; Drug Therapy, Combination
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2-5.
Autorzy:
Ramesh PL; Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Khandelwal P; Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Lakshmy R; Department of Cardiac Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Sinha A; Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Bagga A; Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Hari P; Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India. .
Pokaż więcej
Źródło:
Pediatric nephrology (Berlin, Germany) [Pediatr Nephrol] 2023 Aug; Vol. 38 (8), pp. 2763-2770. Date of Electronic Publication: 2023 Feb 13.
Typ publikacji:
Journal Article
MeSH Terms:
Anticholesteremic Agents*
Heptanoic Acids*/adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/adverse effects
Dyslipidemias*/complications
Dyslipidemias*/diagnosis
Dyslipidemias*/drug therapy
Renal Insufficiency, Chronic*/complications
Renal Insufficiency, Chronic*/chemically induced
Humans ; Child ; Atorvastatin/adverse effects ; Cholesterol, LDL ; Pyrroles/adverse effects ; Cholesterol ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
Autorzy:
Di Costanzo A; Division of Cardiology, Cardiovascular Research Center, University Magna Graecia Catanzaro, 88100 Catanzaro, Italy.
Indolfi C; Division of Cardiology, Cardiovascular Research Center, University Magna Graecia Catanzaro, 88100 Catanzaro, Italy.
Sorrentino S; Division of Cardiology, Cardiovascular Research Center, University Magna Graecia Catanzaro, 88100 Catanzaro, Italy.
Esposito G; Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II, 80134 Naples, Italy.
Spaccarotella CAM; Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II, 80134 Naples, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Jul 21; Vol. 24 (14). Date of Electronic Publication: 2023 Jul 21.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Anticholesteremic Agents*/pharmacology
Anticholesteremic Agents*/therapeutic use
Atherosclerosis*/drug therapy
Cardiovascular Diseases*/drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Hypertriglyceridemia*/drug therapy
Humans ; Cholesterol ; Cholesterol, LDL ; Eicosapentaenoic Acid/pharmacology ; Eicosapentaenoic Acid/therapeutic use ; Ezetimibe/pharmacology ; Ezetimibe/therapeutic use ; Fibrinolytic Agents/pharmacology ; Fibrinolytic Agents/therapeutic use ; PCSK9 Inhibitors ; Proprotein Convertase 9/metabolism ; Triglycerides
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Plasma concentration of atorvastatin metabolites correlates with low-density lipoprotein cholesterol reduction in patients with coronary heart disease.
Autorzy:
Sverre E; Department of Medicine, Drammen Hospital, Vestre Viken Trust, Drammen, Norway.
Munkhaugen J; Department of Medicine, Drammen Hospital, Vestre Viken Trust, Drammen, Norway.; Department of Behavioural Medicine, University of Oslo, Oslo, Norway.
Kristiansen O; Department of Medicine, Drammen Hospital, Vestre Viken Trust, Drammen, Norway.; Department of Behavioural Medicine, University of Oslo, Oslo, Norway.
Weedon-Fekjaer H; Oslo Center for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway.
Peersen K; Department of Cardiology, Vestfold Hospital, Tonsberg, Norway.
Gjertsen E; Department of Medicine, Drammen Hospital, Vestre Viken Trust, Drammen, Norway.
Gullestad L; Oslo University Hospital Rikshospitalet, Oslo, Norway.; KG Jebsen Cardiac Research Center and Center for Heart Failure Research, Oslo University Hospital Ullevål, Oslo, Norway.
Bergan S; Department of Pharmacology, Oslo University Hospital, Oslo, Norway.
Husebye E; Department of Medicine, Drammen Hospital, Vestre Viken Trust, Drammen, Norway.
Vethe NT; Department of Pharmacology, Oslo University Hospital, Oslo, Norway.
Pokaż więcej
Źródło:
Pharmacology research & perspectives [Pharmacol Res Perspect] 2023 Jun; Vol. 11 (3), pp. e01089.
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Anticholesteremic Agents*/therapeutic use
Anticholesteremic Agents*/pharmacology
Heptanoic Acids*/pharmacology
Heptanoic Acids*/therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/adverse effects
Coronary Disease*/drug therapy
Coronary Disease*/chemically induced
Humans ; Atorvastatin/therapeutic use ; Cholesterol, LDL ; Pyrroles ; Triglycerides
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD?
Autorzy:
Reddy V; Department of Family Medicine, University of North Carolina, Chapel Hill.
Allison J; Department of Family Medicine, University of North Carolina, Chapel Hill.
Mounsey A; Department of Family Medicine, University of North Carolina, Chapel Hill.
Pokaż więcej
Źródło:
The Journal of family practice [J Fam Pract] 2023 Jun; Vol. 72 (5), pp. 227-229.
Typ publikacji:
Meta-Analysis; Journal Article
MeSH Terms:
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Cardiovascular Diseases*/prevention & control
Anticholesteremic Agents*/therapeutic use
Adult ; Humans ; Ezetimibe/therapeutic use ; Rosuvastatin Calcium ; Secondary Prevention
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside.
Autorzy:
Kumric M; Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia.
Urlic H; Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia.
Bozic J; Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia.
Vilovic M; Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia.
Ticinovic Kurir T; Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia.; Department of Endocrinology, Diabetes and Metabolic Diseases, University Hospital of Split, 21000 Split, Croatia.
Glavas D; Cardiovascular Diseases Department, University Hospital of Split, 21000 Split, Croatia.
Miric D; Cardiovascular Diseases Department, University Hospital of Split, 21000 Split, Croatia.
Zanchi J; Cardiovascular Diseases Department, University Hospital of Split, 21000 Split, Croatia.
Bradaric-Slujo A; Cardiovascular Diseases Department, University Hospital of Split, 21000 Split, Croatia.
Lozo M; Cardiovascular Diseases Department, University Hospital of Split, 21000 Split, Croatia.
Borovac JA; Cardiovascular Diseases Department, University Hospital of Split, 21000 Split, Croatia.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Apr 29; Vol. 24 (9). Date of Electronic Publication: 2023 Apr 29.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Cardiovascular Diseases*/drug therapy
Cardiovascular Diseases*/etiology
Cardiovascular Diseases*/prevention & control
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Dyslipidemias*/drug therapy
Atherosclerosis*/complications
Anticholesteremic Agents*/adverse effects
Humans ; Cholesterol, LDL
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A human iPSC-derived hepatocyte screen identifies compounds that inhibit production of Apolipoprotein B.
Autorzy:
Liu JT; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, 29425, USA.
Doueiry C; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, 29425, USA.
Jiang YL; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, 29425, USA.
Blaszkiewicz J; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, 29425, USA.
Lamprecht MP; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, 29425, USA.
Heslop JA; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, 29425, USA.
Peterson YK; Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA.
Carten JD; Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, 29425, USA.
Traktman P; Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, 29425, USA.
Yuan Y; Department of Biomedical Engineering, University of Illinois at Chicago, Chicago, IL, 60607, USA.
Khetani SR; Department of Biomedical Engineering, University of Illinois at Chicago, Chicago, IL, 60607, USA.
Twal WO; Grùthan Biosciences LLC, Hollywood, SC, 29449, USA.
Duncan SA; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, 29425, USA. .; Grùthan Biosciences LLC, Hollywood, SC, 29449, USA. .
Pokaż więcej
Źródło:
Communications biology [Commun Biol] 2023 Apr 24; Vol. 6 (1), pp. 452. Date of Electronic Publication: 2023 Apr 24.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Induced Pluripotent Stem Cells*
Homozygous Familial Hypercholesterolemia*
Hyperlipoproteinemia Type II*/drug therapy
Hyperlipoproteinemia Type II*/genetics
Anticholesteremic Agents*/pharmacology
Humans ; Animals ; Mice ; Proprotein Convertase 9/genetics ; Proprotein Convertase 9/pharmacology ; Proprotein Convertase 9/therapeutic use ; Cholesterol, LDL ; Apolipoproteins B/genetics ; Apolipoproteins B/pharmacology ; Apolipoproteins B/therapeutic use ; Hepatocytes
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Inclisiran-A Revolutionary Addition to a Cholesterol-Lowering Therapy.
Autorzy:
Dec A; Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Medyków 18, 40-752 Katowice, Poland.
Niemiec A; Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Medyków 18, 40-752 Katowice, Poland.
Wojciechowska E; Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Medyków 18, 40-752 Katowice, Poland.
Maligłówka M; Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Medyków 18, 40-752 Katowice, Poland.
Bułdak Ł; Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Medyków 18, 40-752 Katowice, Poland.
Bołdys A; Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Medyków 18, 40-752 Katowice, Poland.
Okopień B; Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Medyków 18, 40-752 Katowice, Poland.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Apr 06; Vol. 24 (7). Date of Electronic Publication: 2023 Apr 06.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Proprotein Convertase 9*/metabolism
Anticholesteremic Agents*/adverse effects
Cholesterol ; RNA, Small Interfering/therapeutic use ; Receptors, LDL/genetics ; Receptors, LDL/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The N-Acetylgalactosamine-conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low-density lipoprotein cholesterol reductions.
Autorzy:
Lehoux D; Targanta Therapeutics Inc., Saint Laurent, Quebec, Canada.
Kallend D; The Medicines Company (Schweiz) GmbH, Zurich, Switzerland.
Wijngaard PLJ; The Medicines Company Inc, Parsippany, New Jersey, USA.
Brown AP; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
Zerler B; The Medicines Company Inc, Parsippany, New Jersey, USA.
Pokaż więcej
Źródło:
Pharmacology research & perspectives [Pharmacol Res Perspect] 2023 Apr; Vol. 11 (2), pp. e01080.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Anticholesteremic Agents*/adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Animals ; Atorvastatin ; Proprotein Convertase 9 ; Cholesterol, LDL ; Macaca fascicularis ; Acetylgalactosamine ; RNA, Small Interfering
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus.
Autorzy:
Rakocevic J; Institute of Histology and Embryology 'Aleksandar Đ. Kostić', Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Dobric M; Institute for Cardiovascular Diseases 'Dedinje', 11000 Belgrade, Serbia.; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Vucic R; Cardiology Clinic, University Clinical Center Kragujevac, 34000 Kragujevac, Serbia.; Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Furtula M; Institute for Cardiovascular Diseases 'Dedinje', 11000 Belgrade, Serbia.
Zaletel I; Institute of Histology and Embryology 'Aleksandar Đ. Kostić', Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Milutinovic K; Institute of Histology and Embryology 'Aleksandar Đ. Kostić', Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Ilijevski A; Institute of Histology and Embryology 'Aleksandar Đ. Kostić', Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Borovic ML; Institute of Histology and Embryology 'Aleksandar Đ. Kostić', Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Tomasevic M; Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.; Cardiology Clinic, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Bajcetic M; Institute of Histology and Embryology 'Aleksandar Đ. Kostić', Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Mar 22; Vol. 24 (6). Date of Electronic Publication: 2023 Mar 22.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Proprotein Convertase 9*/genetics
Proprotein Convertase 9*/metabolism
Anticholesteremic Agents*/adverse effects
Humans ; Cholesterol, LDL ; RNA, Small Interfering/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Beneficial Effect of Cuban Policosanol on Blood Pressure and Serum Lipoproteins Accompanied with Lowered Glycated Hemoglobin and Enhanced High-Density Lipoprotein Functionalities in a Randomized, Placebo-Controlled, and Double-Blinded Trial with Healthy Japanese.
Autorzy:
Cho KH; Raydel Research Institute, Medical Innovation Complex, Daegu 41061, Republic of Korea.; LipoLab, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Nam HS; Raydel Research Institute, Medical Innovation Complex, Daegu 41061, Republic of Korea.
Baek SH; Raydel Research Institute, Medical Innovation Complex, Daegu 41061, Republic of Korea.
Kang DJ; Raydel Research Institute, Medical Innovation Complex, Daegu 41061, Republic of Korea.
Na H; Raydel Research Institute, Medical Innovation Complex, Daegu 41061, Republic of Korea.
Komatsu T; Center for Preventive, Anti-Aging and Regenerative Medicine, Fukuoka University Hospital, 8-19-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan.
Uehara Y; Center for Preventive, Anti-Aging and Regenerative Medicine, Fukuoka University Hospital, 8-19-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan.; Faculty of Sports and Health Science, Fukuoka University, 8-19-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Mar 08; Vol. 24 (6). Date of Electronic Publication: 2023 Mar 08.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Lipoproteins, HDL*/pharmacology
Anticholesteremic Agents*/pharmacology
Humans ; Blood Pressure ; Glycated Hemoglobin ; East Asian People ; Fatty Alcohols/pharmacology ; Lipoproteins/pharmacology ; Double-Blind Method
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells.
Autorzy:
Zulkapli R; Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM), Universiti Teknologi MARA (UiTM), Sungai Buloh Campus, Jalan Hospital, Sungai Buloh 47000, Selangor, Malaysia.; Faculty of Medicine, Universiti Teknologi MARA (UiTM), Sungai Buloh Campus, Jalan Hospital, Sungai Buloh 47000, Selangor, Malaysia.; Faculty of Dentistry, Universiti Teknologi MARA (UiTM), Sungai Buloh Campus, Jalan Hospital, Sungai Buloh 47000, Selangor, Malaysia.
Muid SA; Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM), Universiti Teknologi MARA (UiTM), Sungai Buloh Campus, Jalan Hospital, Sungai Buloh 47000, Selangor, Malaysia.; Faculty of Medicine, Universiti Teknologi MARA (UiTM), Sungai Buloh Campus, Jalan Hospital, Sungai Buloh 47000, Selangor, Malaysia.
Wang SM; Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM), Universiti Teknologi MARA (UiTM), Sungai Buloh Campus, Jalan Hospital, Sungai Buloh 47000, Selangor, Malaysia.; Faculty of Medicine, Universiti Teknologi MARA (UiTM), Sungai Buloh Campus, Jalan Hospital, Sungai Buloh 47000, Selangor, Malaysia.
Nawawi H; Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM), Universiti Teknologi MARA (UiTM), Sungai Buloh Campus, Jalan Hospital, Sungai Buloh 47000, Selangor, Malaysia.; Faculty of Medicine, Universiti Teknologi MARA (UiTM), Sungai Buloh Campus, Jalan Hospital, Sungai Buloh 47000, Selangor, Malaysia.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Mar 07; Vol. 24 (6). Date of Electronic Publication: 2023 Mar 07.
Typ publikacji:
Journal Article
MeSH Terms:
Atherosclerosis*/metabolism
Anticholesteremic Agents*/therapeutic use
Humans ; PCSK9 Inhibitors ; Proprotein Convertase 9/genetics ; Endothelial Cells/metabolism ; NF-kappa B/metabolism ; Coronary Vessels/metabolism ; Biomarkers
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Monitoring policy in the context of preventive treatment of cardiovascular disease.
Autorzy:
Otero-Leon DF; Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor, MI, 48109, USA. .
Lavieri MS; Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor, MI, 48109, USA.
Denton BT; Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor, MI, 48109, USA.
Sussman J; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
Hayward RA; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
Pokaż więcej
Źródło:
Health care management science [Health Care Manag Sci] 2023 Mar; Vol. 26 (1), pp. 93-116. Date of Electronic Publication: 2022 Oct 26.
Typ publikacji:
Journal Article
MeSH Terms:
Cardiovascular Diseases*/prevention & control
Anticholesteremic Agents*
Humans ; Risk Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia.
Autorzy:
Ebenezer O; Department of Chemistry, Faculty of Natural Science, Mangosuthu University of Technology, Umlazi 4031, South Africa.
Comoglio P; Department of Mechanical and Aerospace Engineering (DIMEAS), Politecnico di Torino, 10129 Turin, Italy.
Wong GK; Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada.; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2E1, Canada.
Tuszynski JA; Department of Mechanical and Aerospace Engineering (DIMEAS), Politecnico di Torino, 10129 Turin, Italy.; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2E1, Canada.; Department of Physics, University of Alberta, Edmonton, AB T6G 2E1, Canada.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Feb 16; Vol. 24 (4). Date of Electronic Publication: 2023 Feb 16.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Anticholesteremic Agents*/therapeutic use
Cardiovascular Diseases*/drug therapy
Hypercholesterolemia*/metabolism
Hypercholesterolemia*/therapy
RNA, Small Interfering*/therapeutic use
Humans ; Antibodies, Monoclonal/therapeutic use ; Cholesterol, LDL ; Proprotein Convertase 9/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Association between sociodemographic factors and cholesterol-lowering medication use in U.S. adults post-myocardial infarction.
Autorzy:
Mansi ET; School of Public Health, University of Washington, Seattle, Washington, United States of America.; Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom.
Banks S; School of Public Health, University of Washington, Seattle, Washington, United States of America.
Littman AJ; School of Public Health, University of Washington, Seattle, Washington, United States of America.; Seattle Epidemiologic Research and Information Center, Department of Veterans Affairs Puget Sound Health Care System, Seattle, Washington, United States of America.; Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care, Health Services, Seattle, Washington, United States of America.
Weiss NS; School of Public Health, University of Washington, Seattle, Washington, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Feb 09; Vol. 18 (2), pp. e0281607. Date of Electronic Publication: 2023 Feb 09 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Anticholesteremic Agents*/therapeutic use
Myocardial Infarction*/drug therapy
Myocardial Infarction*/epidemiology
Myocardial Infarction*/prevention & control
Humans ; Aged ; Cross-Sectional Studies ; Sociodemographic Factors ; Surveys and Questionnaires ; Cholesterol
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells.
Autorzy:
Woźniak E; Department of Internal Diseases and Clinical Pharmacology, Laboratory of Tissue Immunopharmacology, Medical University of Lodz, Lodz, Poland.
Broncel M; Department of Internal Diseases and Clinical Pharmacology, Laboratory of Tissue Immunopharmacology, Medical University of Lodz, Lodz, Poland.
Niedzielski M; Department of Internal Diseases and Clinical Pharmacology, Laboratory of Tissue Immunopharmacology, Medical University of Lodz, Lodz, Poland.
Woźniak A; Department of Internal Diseases and Clinical Pharmacology, Laboratory of Tissue Immunopharmacology, Medical University of Lodz, Lodz, Poland.
Gorzelak-Pabiś P; Department of Internal Diseases and Clinical Pharmacology, Laboratory of Tissue Immunopharmacology, Medical University of Lodz, Lodz, Poland.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Feb 08; Vol. 18 (2), pp. e0280741. Date of Electronic Publication: 2023 Feb 08 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Anticholesteremic Agents*/therapeutic use
Atherosclerosis*/drug therapy
Humans ; Rosuvastatin Calcium/therapeutic use ; Atorvastatin/therapeutic use ; Interleukin-10 ; Interleukin-18/genetics ; Endothelial Cells ; Ezetimibe/therapeutic use ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use ; Transforming Growth Factor beta ; RNA, Messenger/genetics ; Interleukin-23 ; Drug Therapy, Combination
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia.
Autorzy:
Larrey D; University Hospital of Montpellier, Montpellier, France.
D'Erasmo L; Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.
O'Brien S; Amryt Pharmaceuticals DAC, Dublin, Ireland.
Arca M; Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.
Pokaż więcej
Corporate Authors:
Italian Working Group on Lomitapide
Źródło:
Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2023 Feb; Vol. 43 (2), pp. 413-423. Date of Electronic Publication: 2022 Dec 30.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Anticholesteremic Agents*/adverse effects
Homozygous Familial Hypercholesterolemia*
Hyperlipoproteinemia Type II*/drug therapy
Hyperlipoproteinemia Type II*/chemically induced
Humans ; Biomarkers ; Cholesterol, LDL/therapeutic use ; Homozygote ; Liver ; Vitamins/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study.
Autorzy:
Al Faraidy K; KFMMC Cardiac Center, Interventional Cardiologist, King Fahd Military Medical Complex, Dharan, Saudi Arabia.
Akbar M; Cardiology Unit, Sabah Hospital, Kuwait City, Kuwait.
Shehri M; Cardiac Center Armed Forces Hospital Southern Region, Khamis Mushait, Saudi Arabia.
Aljarallah M; Sabah Al Ahmed Cardiac Center, Al-Amiri Hospital, Kuwait City, Kuwait.
Abdin Hussein G; Adult Cardiology Department, Cardiac Center North West Armed Forces King Salman Hospital, Tabuk, Saudi Arabia.
Dashti R; Sabah Al-Ahmad Cardiac Center, Amiri Hospital, Kuwait City, Kuwait.
Al Qudaimi A; Saud Al-babtain Cardiac Center, Dammam, Saudi Arabia.
Al Nouri F; Cardiovascular Prevention Unit, Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia.
Awan Z; King Abdulaziz University, Clinical Biochemistry Jeddah University, Jeddah, Saudi Arabia.
Essam A; Medical Affair Department, Amgen Middle East, Dubai, United Arab of Emirates.
Emara A; Medical Department, Amgen Saudi, Saudi Arabia.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Jan 20; Vol. 18 (1), pp. e0278821. Date of Electronic Publication: 2023 Jan 20 (Print Publication: 2023).
Typ publikacji:
Observational Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Anticholesteremic Agents*/adverse effects
Hyperlipidemias*/drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Adult ; Humans ; Cholesterol, LDL ; Prospective Studies ; Kuwait/epidemiology ; Saudi Arabia ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors.
Autorzy:
Choi HD; College of Pharmacy, Yeungnam University, Gyeongbuk, Republic of Korea.
Kim JH; College of Pharmacy, Yeungnam University, Gyeongbuk, Republic of Korea.
Pokaż więcej
Źródło:
Cardiovascular therapeutics [Cardiovasc Ther] 2023 Jan 04; Vol. 2023, pp. 7362551. Date of Electronic Publication: 2023 Jan 04 (Print Publication: 2023).
Typ publikacji:
Meta-Analysis; Journal Article
MeSH Terms:
Anticholesteremic Agents*/therapeutic use
Cardiovascular Diseases*/diagnosis
Cardiovascular Diseases*/epidemiology
Cardiovascular Diseases*/prevention & control
PCSK9 Inhibitors*/therapeutic use
Humans ; Antibodies, Monoclonal/therapeutic use ; Subtilisin/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-25 z 6500

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies